Universität zu Köln

Journal Article

Javle, Milind, Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa ORCID: 0000-0002-5856-4082, Weiss, Karl Heinz, Waldschmidt, Dirk-Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony, Borad, Mitesh J., Yong, Wei Peng, Philip, Philip A., Bitzer, Michael, Tanasanvimon, Surbpong, Li, Ai, Pande, Amit, Soifer, Harris S., Shepherd, Stacie Peacock, Moran, Susan, Zhu, Andrew X., Bekaii-Saab, Tanios S. and Abou-Alfa, Ghassan K. (2021). Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol. Hepatol., 6 (10). S. 803 - 816. SAN DIEGO: ELSEVIER INC. ISSN 2468-1253

Javle, Milind M., Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa, Waldschmidt, Dirk Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony B., Yong, Wei-Peng, Philip, Philip Agop, Bitzer, Michael, Tanasanvimon, Suebpong, Pande, Amit, Shepherd, Stacie Peacock, Moran, Susan and Abou-Alfa, Ghassan K. (2021). Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J. Clin. Oncol., 39 (3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Makawita, Shalini, Kelley, Robin Kate, Roychowdhury, Sameek, Weiss, Karl Heinz, Abou-Alfa, Ghassan K., Macarulla, Teresa, Sadeghi, Saeed, Waldschmidt, Dirk, Zhu, Andrew X., Goyal, Lipika, Yong, Wei-Peng, Borbath, Ivan, El-Khoueiry, Anthony B., Philip, Philip Agop, Moran, Susan, Ye, Yining, Soifer, Harris S., Li, Gary, Berman, Craig and Javle, Milind M. (2020). Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions. J. Clin. Oncol., 38 (4). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Shigeta, Kohei, Matsui, Aya, Kikuchi, Hiroto, Klein, Sebastian ORCID: 0000-0002-2188-9377, Mamessier, Emilie, Chen, Ivy X., Aoki, Shuichi, Kitahara, Shuji ORCID: 0000-0002-2904-0319, Inoue, Koetsu, Shigeta, Ayako, Hato, Tai, Ramjiawan, Rakesh R., Staiculescu, Daniel, Zopf, Dieter, Fiebig, Lukas, Hobbs, Gabriela S., Quaas, Alexander, Dima, Simona, Popescu, Irinel, Huang, Peigen, Munn, Lance L., Cobbold, Mark, Goyal, Lipika, Zhu, Andrew X., Jain, Rakesh K. and Duda, Dan G. (2020). Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J. Immunother. Cancer, 8 (2). LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426